Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2022-502827-23-00Phase 2Completed
Phase 2, randomised, double-blind trial in chronic hand dermatitis (CHE) comparing Ruxolitinib cream with Vehicle then ruxolitinib cream (2 arms). Primary endpoint: Investigator Global Assessment-CHE treatment success at Week 16. Started Sep 2023; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2022-502827-23-00.